{"entity":{"id":"taxane","kind":"term","name":"Taxanes (paclitaxel, docetaxel, nab-paclitaxel)","aka":["taxanes","taxane-based","taxane-pretreated","post-taxane","taxane-naive","weekly paclitaxel","gemcitabine/nab-paclitaxel","carboplatin/paclitaxel"],"tldr":"Chemotherapy drugs originally from the yew tree that freeze the cell's internal scaffolding (microtubules) so it cannot divide. Used in breast, lung, ovarian, prostate, gastric and head and neck cancers; their main lasting side effect is nerve damage in the hands and feet.","summary":"Paclitaxel (Taxol, 1992) and docetaxel are given with platinum in ovarian and lung cancer, sequentially with anthracyclines in breast cancer, as the chemotherapy partner in KEYNOTE-522 and CLEOPATRA, and as first chemotherapy in prostate cancer (docetaxel, then cabazitaxel after progression). Nab-paclitaxel is an albumin-bound form that avoids solvent hypersensitivity and is standard with gemcitabine in pancreatic cancer. Peripheral neuropathy, alopecia, neutropenia and hypersensitivity reactions are the main toxicities; taxane-derived payloads are less common in ADCs than tubulin inhibitors such as MMAE, which act on the same target.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Taxane","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Taxane"}],"tags":[],"related":["peripheral-neuropathy","tubulin-inhibitor-payloads","doublet-triplet"],"cancers":[],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["paclitaxel","docetaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Treatment jargon"},"route":"/terms/taxane/","neighbours":{"term":[{"id":"doublet-triplet","kind":"term","name":"Doublet, triplet and quadruplet regimens","route":"/terms/doublet-triplet/"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/"},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"paper":[{"id":"paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012","kind":"paper","name":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","route":"/key-papers/paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012/"},{"id":"paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021","kind":"paper","name":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","route":"/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}